Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock.
Zura Bio Limited - Class A Ordinary shares (ZURA)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ZURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZURA alerts
High impacting Zura Bio Limited - Class A Ordinary shares news events
Weekly update
A roundup of the hottest topics
ZURA
News
- Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic SclerosisBusiness Wire
- Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Zura Bio Limited (NASDAQ: ZURA) had its price target lowered by analysts at Chardan Capital from $14.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesBusiness Wire
ZURA
Earnings
- 11/7/24 - Miss
ZURA
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ZURA's page on the SEC website